No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
STRO Sutro Biopharma
- 2.960
- -0.090-2.95%
Close Jul 2 16:00 ET
- 3.040
- +0.080+2.70%
Post 18:17 ET
242.11MMarket Cap-1574P/E (TTM)
3.040High2.820Low621.48KVolume3.040Open3.050Pre Close1.82MTurnover1.03%Turnover RatioLossP/E (Static)81.79MShares6.13052wk High2.47P/B178.74MFloat Cap2.00552wk Low--Dividend TTM60.39MShs Float28.300Historical High--Div YieldTTM7.21%Amplitude2.005Historical Low2.926Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 28%
Unfortunately for some shareholders, the Sutro Biopharma, Inc. (NASDAQ:STRO) share price has dived 28% in the last thirty days, prolonging recent pain. The drop over the last 30 days has capped off
Institutional Owners May Take Dramatic Actions as Sutro Biopharma, Inc.'s (NASDAQ:STRO) Recent 17% Drop Adds to One-year Losses
Key Insights Given the large stake in the stock by institutions, Sutro Biopharma's stock price might be vulnerable to their trading decisions A total of 13 investors have a majority stake in the com
Express News | Vgxi Inc. Announces a Strategic Partnership With Sutro Biopharma Inc. to Support Growing Clinical Pipeline
Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable
Coping With a Wild Ride: Investing in Sutro Biopharma (NASDAQ:STRO)
BofA Securities Maintains Sutro Biopharma(STRO.US) With Buy Rating
BofA Securities analyst Tazeen Ahmad maintains $Sutro Biopharma(STRO.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 46.5% and a total average return of 0.2% over
Comments
$Sutro Biopharma(STRO.US$ Completion of enrollment for Part One of the Phase II/III REFRaME-O1 trial for Luvelta and the anticipation of an update that could affirm its potential, which is estimated to be significantly greater than its competitor, Elahere, in platinum-resistant ovarian cancer (PROC). Bancroft highlights Luvelta’s ability to serve a wider PROC patient base, with the potential to address about 80% of patients expressing folate receptor alpha (FRα), in contr...
3
$Sutro Biopharma(STRO.US$ Sutro Biopharma Initiated at Buy by B of A Securities with a PT of 12.00!
Dow Jones· 2 mins ago
Dow Jones· 2 mins ago
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
$Sutro Biopharma(STRO.US$ Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
GlobeNewswire· 10 mins ago
GlobeNewswire· 10 mins ago
1
$Sutro Biopharma(STRO.US$ Sutro Biopharma Inc (STRO) has provided an announcement.
Sutro Biopharma, Inc. has secured a lucrative Exclusive License Agreement with Ipsen Pharma SAS to grant exclusive rights for the research, development, manufacture, and commercialization of STRO-003, a promising biopharmaceutical product. Ipsen has committed to an initial payment of $50 million and an investment of $25 million in Sutro Biopharma’s shares at a premium. Additional financial milestones includ...
Sutro Biopharma, Inc. has secured a lucrative Exclusive License Agreement with Ipsen Pharma SAS to grant exclusive rights for the research, development, manufacture, and commercialization of STRO-003, a promising biopharmaceutical product. Ipsen has committed to an initial payment of $50 million and an investment of $25 million in Sutro Biopharma’s shares at a premium. Additional financial milestones includ...
1
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg